ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R2‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma
Abstract
Introduction: The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) continues to convey inferior survival despite efforts to enhance outcomes with novel R-CHOP combinations. Phase II studies have suggested that the addition of the immunomodulatory agent lenalidomide to R-CHOP could ameliorate the poor prognostic effect of the ABC phenotype and improve treatment outcome in this subgroup of patients. Methods: The global phase III ROBUST trial (NCT02285062) is the first to compare lenalidomide/R-CHOP (R2-CHOP) vs placebo/R-CHOP in previously untreated, prospectively selected, CD20+ ABC-type DLBCL. Patients included adults with Ann Arbor stage II-IV disease, IPI score ≥ 2, and ECOG PS ≤ 2. Confirmation of histology and cell-of-origin type were prospectively analyzed from formalin-fixed, paraffin-embedded excisional/surgical or core needle biopsy samples by central pathology using the NanoString Lymphoma Subtyping Test (LST), based on the Lymph2Cx GEP assay (Scott, Blood 2014). ABC-DLBCL patients were stratified by IPI score (2 vs ≥ 3), bulky disease (< 7 vs ≥ 7 cm) and age (< 65 vs ≥ 65 y), and randomized 1:1 to lenalidomide PO 15 mg/d, d1-14/21 + standard R-CHOP21 vs placebo/R-CHOP21 for 6 cycles, with 2 additional, optional doses of rituximab per local practice. The primary endpoint was progression-free survival (PFS) assessed by independent central radiology per 2014 NHL IWG criteria, and defined as time from randomization to PD or death from any cause. Results: A total of 570 ABC-DLBCL patients met eligibility criteria and were enrolled in ROBUST (n = 285 per arm). Baseline demographics were similar between arms, with a median age for all patients of 65 y (52% ≥ 65 y), 42% IPI 2 score/58% IPI ≥ 3 score, 88% stage III/IV disease, and 34% bulky disease. The primary endpoint of PFS was not met with an HR = 0.85 (95% CI, 0.63-1.14) and P = 0.29; median PFS was not reached for either arm (Figure). Positive PFS trends favoring R2-CHOP over placebo/R-CHOP were observed with disease stage III/IV (HR = 0.81 [95% CI, 0.60-1.10]) and IPI score ≥ 3 (HR = 0.74 [95% CI, 0.53-1.05]). Median EFS was not reached for either arm (HR = 1.04; 95% CI, 0.80-1.34; P = 0.73). At a median follow-up of 27.1 mo (range, 0-47) for survivors, 2-y OS was 79% for R2-CHOP and 80% for placebo/R-CHOP (medians not reached). ORR was 91% for both arms, with 69% vs 65% CR for R2-CHOP vs placebo/R-CHOP, respectively. 74% R2-CHOP and 84% placebo/R-CHOP patients completed 6 cycles of treatment; AEs (mainly neutropenia) were the most common reason for treatment discontinuation. The most common grade 3/4 AEs (≥ 10%) for R2-CHOP vs placebo/R-CHOP were neutropenia (60% vs 48%), anemia (22% vs 14%), thrombocytopenia (17% vs 11%), leukopenia (14% vs 15%), febrile neutropenia (14% vs 9%), and lymphopenia (11% vs 8%).
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Avadomide has been tested in clinical trials involving patients with R/R DLBCL, demonstrating promising single-agent activity (ORR 29% and CR rate 11%).
“Avadomide has been tested in clinical trials involving patients with R/R DLBCL, demonstrating promising single-agent activity (ORR 29% and CR rate 11%)85.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [85]
Cited by
Sorted by citations
New agents and regimens for diffuse large B cell lymphoma
Wang, L., Li, L., & Young, K. H. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01011-z · Cited by 174 · see citing works
“However, the phase 3 ROBUST study in untreated ABC-DLBCL did not meet the primary endpoint of PFS, though positive PFS trends favoring R2-CHOP21 were observed in those with high international prognostic index (IPI) scores and advanced disease stages [36].”
BackgroundResultCancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137 · see citing works
Nowakowski, G. S., Hong, F., Scott, D. W., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01375 · Cited by 110 · see citing works
Self-citationToward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma
Ennishi, D., Hsi, E. D., Steidl, C., & Scott, D. W. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0174 · Cited by 96 · see citing works
Self-citationRivas‐Delgado, A., Nadeu, F., Enjuanes, A., Casanueva-Eliceiry, S., Mozas, P., Magnano, L., de Anta, N. C., Rovira, J., Dlouhy, I., Martín, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2558 · Cited by 96 · see citing works
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients
Di, M., Huntington, S. F., & Olszewski, A. J. (2020) · The Oncologist · doi:10.1002/onco.13610 · Cited by 81 · see citing works
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA
Gouill, S. L., Ghesquières, H., Obéric, L., et al. (2020) · Blood · doi:10.1182/blood.2020008750 · Cited by 78 · see citing works
Obéric, L., Peyrade, F., Puyade, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02666 · Cited by 72 · see citing works
Lemonnier, F., Safar, V., Beldi‐Ferchiou, A., Cottereau, A., Bachy, E., Cartron, G., Fataccioli, V., Pelletier, L., Robe, C., Letourneau, A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003081 · Cited by 67 · see citing works
Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas
Reimann, M., Schrezenmeier, J., Richter-Pechanska, P., Dolnik, A., Hick, T. P., Schleich, K., Cai, X., Fan, D. N. Y., Lohneis, P., Maßwig, S., et al. (2021) · Blood · doi:10.1182/blood.2020005244 · Cited by 59 · see citing works
McMillan, A., Phillips, E. H., Kirkwood, A. A., Barrans, S., Burton, C. H., Rule, S. A., Patmore, R. D., Pettengell, R., Ardeshna, K. M., Lawrie, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.016 · Cited by 63 · see citing works
Wilson, M. R., Eyre, T. A., Martínez‐Calle, N., Ahearne, M. J., Parsons, K. E., Preston, G., Khwaja, J., Schofield, J., Elliot, J., kh, A. M., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002421 · Cited by 54 · see citing works
Chamuleau, M. E. D., Burggraaff, C. N., Nijland, M., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.238162 · Cited by 54 · see citing works
“Against expectation, R2CHOP did not result in a survival advantage in ABC-subtype DLBCL, as has recently been shown in a phase III study (ROBUST).(17) The present study reports the results of a prospective single-arm phase II trial forMYC+ LBCL patients treated with R2CHOP.”
Investigational drugs for the treatment of diffuse large B-cell lymphoma
Patriarca, A., & Gaïdano, G. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1855140 · Cited by 47 · see citing works
Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL
Hartert, K. T., Wenzl, K., Krull, J. E., Manske, M. K., Sarangi, V., Asmann, Y. W., Larson, M. C., Maurer, M. J., Slager, S. L., Macon, W. R., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0766-4 · Cited by 49 · see citing works
Self-citationCandelaria, M., & Dueñas‐González, A. (2021) · Therapeutic Advances in Hematology · doi:10.1177/2040620721989579 · Cited by 44 · see citing works
Khurana, A., Mwangi, R., Nowakowski, G. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01935 · Cited by 39 · see citing works
“Lenalidomide added to R-CHOP was evaluated in two trials, a randomized phase II ECOG 1412 and the phase III ROBUST.11,17,18 Patients percent exclusion based on the criteria from the ROBUST trial was 10.0%.”
MethodResultInfluentialSelf-citationMartin, P., Bartlett, N. L., Chávez, J. C., et al. (2021) · Blood · doi:10.1182/blood.2021011679 · Cited by 38 · see citing works
Bourbon, E., & Salles, G. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1800638 · Cited by 34 · see citing works
Lue, J. K., & O’Connor, O. A. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30222-2 · Cited by 32 · see citing works
Recent survival trends in diffuse large B‐cell lymphoma––Have we made any progress beyond rituximab?
Epperla, N., Vaughn, J. L., Othus, M. K. D., Hallack-Neto, A. E., & Costa, L. J. (2020) · Cancer Medicine · doi:10.1002/cam4.3237 · Cited by 32 · see citing works
Yamshon, S., & Ruan, J. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00536-6 · Cited by 30 · see citing works
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma
Rossi, A., Orecchioni, S., Falvo, P., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01347-6 · Cited by 28 · see citing works
Self-citationThe PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas
Garcia-Lacarte, M., Grijalba, S. C., Melchor, J., Arnaiz-Leché, A., & Roa, S. (2021) · Cancers · doi:10.3390/cancers13184683 · Cited by 31 · see citing works
Diffuse Large B-Cell Lymphoma’s New Genomics: The Bridge and the Chasm
Crombie, J. L., & Armand, P. A. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01501 · Cited by 25 · see citing works
Papageorgiou, S. G., Thomopoulos, T. P., Katagas, I., Bouchla, A., & Pappa, V. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211013987 · Cited by 29 · see citing works
Cost burden of diffuse large B-cell lymphoma
Harkins, R. A., Patel, S. P., & Flowers, C. R. (2019) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2019.1680288 · Cited by 25 · see citing works
“R-CHOP from the ROBUST trial demonstrated no benefit for the experimental arm in patients with ABC-DLBCL [70].”
BackgroundInfluentialLoh, Z., Salvaris, R., Chong, G., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17436 · Cited by 23 · see citing works
“These challenges are reflected to a degree in the comparison of time-to-treatment and negative prognostic associations in real-world, trial and biomarker-driven DLBCL trial populations reported to date.(12,16) However, newer trials continue to fail to address these issues.”
BackgroundThe use of frailty assessments in treating older adults with aggressive lymphomas
Córdoba, R., Luminari, S., & Eyre, T. A. (2021) · British Journal of Haematology · doi:10.1111/bjh.17384 · Cited by 20 · see citing works
Malecek, M., Watkins, M. P., & Bartlett, N. L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1777979 · Cited by 20 · see citing works
“(OS), and a Phase III trial of lenalidomide in combination with R-CHOP for non-CGB DLBCL was negative [17,25].”
BackgroundRoh, J., Cho, H., Pak, H.-K., Lee, Y. S., Lee, S.-W., Ryu, J., Chae, E. J., Kim, K. W., Huh, J., Choi, Y. S., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00962-z · Cited by 21 · see citing works
Self-citationRødland, G. E., Melhus, K. B., Generalov, R., Gilani, S., Bertoni, F., Dahle, J., Syljuåsen, R. G., & Patzke, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01301 · Cited by 19 · see citing works
Nowakowski, G. S., Willenbacher, W., Greil, R., et al. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03241-4 · Cited by 18 · see citing works
Self-citationPredictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas
Pileri, S. A., Tripodo, C., Melle, F., Motta, G., Tabanelli, V., Fiori, S., Vegliante, M. C., Mazzara, S., Ciavarella, S., & Derenzini, E. (2021) · Cells · doi:10.3390/cells10030675 · Cited by 18 · see citing works
The use of tafasitamab in diffuse large B-cell lymphoma
Düll, J., Topp, M. S., & Salles, G. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211027458 · Cited by 16 · see citing works
Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment
Danilov, A. V., Magagnoli, M., & Matasar, M. J. (2022) · The Oncologist · doi:10.1093/oncolo/oyab004 · Cited by 14 · see citing works
Pasvolsky, O., Rozental, A., Raanani, P., et al. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1898048 · Cited by 14 · see citing works
“Six trials included all DLBCL patients regardless of cell of origin [11,12,14–16,19], whereas four trials included only patients with non-GCB/ABC DLBCL [13,17,18,20].”
BackgroundChiappella, A., Crombie, J. L., Guidetti, A., Vitolo, U., Armand, P. A., & Corradini, P. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000284 · Cited by 14 · see citing works
Self-citationFrontzek, F., & Lenz, G. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1683447 · Cited by 13 · see citing works
“It took 27 days in the PHOENIX trial, 31 days in ROBUST, and 21 days in the Alliance study until treatment was initiated [13,14,85].”
MethodResultBlunt, D. N., Smyth, L., Nagamuthu, C., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7654 · Cited by 13 · see citing works
El‐Galaly, T. C., Cheah, C. Y., Kristensen, D. T., Hutchison, A., Hay, K. A., Callréus, T., & Villa, D. R. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1741680 · Cited by 13 · see citing works
Cherng, H.-J. J., & Westin, J. R. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1869228 · Cited by 13 · see citing works
“Patients with stage II–IV disease and an IPI 2 were eligible for both studies, however E1412 enrolled more patients with higher risk features compared to ROBUST: 66% versus 58% had an IPI 3, and 97% versus 87% had stage III–IV disease [33].”
BackgroundInfluentialHarkins, R. A., Patel, S. P., Lee, M. J., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006504 · Cited by 11 · see citing works
Derenzini, E., Mazzara, S., Melle, F., Motta, G., Fabbri, M., Bruna, R., Agostinelli, C., Cesano, A., Corsini, C. A., Chen, N., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.236455 · Cited by 12 · see citing works
Self-citationDoraiswamy, A., Shah, M. R., & Bannerji, R. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00610-y · Cited by 11 · see citing works
Wight, J. C., Hamad, N., Campbell, B. A., Ku, M., Lee, K. M. L., Rose, H. L., Armytage, T., Latimer, M., Lee, H., Lee, S. T., et al. (2021) · Internal Medicine Journal · doi:10.1111/imj.15533 · Cited by 10 · see citing works
Targeting CD20: teaching an old dog new tricks
Sharman, J. P. (2019) · Hematology · doi:10.1182/hematology.2019000031 · Cited by 10 · see citing works
Suzuki, T., Maruyama, D., Miyagi‐Maeshima, A., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4062 · Cited by 10 · see citing works
Self-citationBcl-2 inhibition in DLBCL: “the times they are a-changing”?
Vitolo, U., & Novo, M. (2021) · Blood · doi:10.1182/blood.2020008924 · Cited by 9 · see citing works
Self-citationFerreri, A. J. M., Sassone, M. C., Angelillo, P., Zaja, F. F., Re, A., Rocco, A. D., Spina, M., Fabbri, A., Stelitano, C. C., Frezzato, M., et al. (2020) · Hematological Oncology · doi:10.1002/hon.2742 · Cited by 8 · see citing works
“The main difficulty to put these results in context are related to the fact that available randomized studies focused on lenalidomide maintenance (ie, ROBUST,(22) ECOG-ACRIN-1412,(23) and REMARC(21) trials) regard exclusively patients with newly diagnosed DLBCL, and show contrasting results.(22,23) Differences in desi…”
BackgroundMendeville, M., Janssen, J., Vries, G. T. L.-D., van Dijk, E., Richter, J., Nijland, M., Roemer, M. G. M., Stathi, P., Hijmering, N. J., Bladergroen, R. S., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55614-y · Cited by 7 · see citing works
Denker, S., Bittner, A., Na, I., Kase, J., Frick, M., Anagnostopoulos, I., Hummel, M., & Schmitt, C. A. (2019) · International Journal of Hematologic Oncology · doi:10.2217/ijh-2019-0010 · Cited by 8 · see citing works
Efficacy of lenalidomide in high‐risk diffuse large B‐cell lymphoma
Rodgers, T. D., Baran, A. M., Reagan, P. M., Casulo, C., Zent, C. S., Evans, A., Burack, R., Williams, A. M., Friedberg, J. W., & Barr, P. M. (2019) · British Journal of Haematology · doi:10.1111/bjh.16302 · Cited by 8 · see citing works
Wilson, W. H., Phillips, T. J., Popplewell, L. L., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1907371 · Cited by 8 · see citing works
“However, lenalidomide combined with R-CHOP did not significantly prolong PFS versus R-CHOP alone (hazard ratio, 0.85; 95% confidence interval [CI], 0.63–1.14; p = 0.29) in first-line ABC DLBCL [24].”
InfluentialPredicting primary treatment failure using interim FDG‐PET scanning in diffuse large B‐cell lymphoma
Wight, J. C., Wai, S. H., Shen, E., et al. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13684 · Cited by 8 · see citing works
Treatment of Aggressive B Cell Lymphomas: Updates in 2019
Mondello, P., & Nowakowski, G. S. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00581-6 · Cited by 8 · see citing works
Self-citationNavigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL
Munoz, J. L., Deshpande, A. J., Rimsza, L. M., Nowakowski, G. S., & Kurzrock, R. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102691 · Cited by 7 · see citing works
Self-citationNovel synthetic drugs for the treatment of non-Hodgkin lymphoma
Manji, F., Puckrin, R., & Stewart, D. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1902988 · Cited by 7 · see citing works
Upcoming immunotherapeutic combinations for B-cell lymphoma
Greve, P. F., Meyer‐Wentrup, F. A. G., Peperzak, V., & Boes, M. L. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab001 · Cited by 6 · see citing works
Ibrutinib and lenalidomide: when 1+1 = >2
Westin, J. R. (2019) · Blood · doi:10.1182/blood.2019002237 · Cited by 6 · see citing works
Ednersson, S. B., Stern, M., Fagman, H., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1913147 · Cited by 5 · see citing works
Narrative review: secondary central nervous system lymphoma
Steffanoni, S., & Doorduijin, J. K. (2021) · Annals of Lymphoma · doi:10.21037/aol-20-39 · Cited by 5 · see citing works
“Lenalidomide and ibrutinib, two novel agents that were incorporated into R-CHOP therapy in two large phase 3 trials, have failed to show overall benefit for untreated patients with DLBCL (42,43).”
BackgroundSayed, R. E., Darsa, H. E., Kort, J., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.05.011 · Cited by 5 · see citing works
Aggressive B-Cell Lymphoma: Chasing the Target
Walewski, J. A. (2019) · Journal of Investigative Medicine · doi:10.1136/jim-2019-001169 · Cited by 5 · see citing works
Bazzell, B. G., Benitez, L. L., Marini, B. L., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.12.018 · Cited by 3 · see citing works
Immuno-oncology for B-cell lymphomas
Choi, Y. S. (2021) · Blood Research · doi:10.5045/br.2021.2021032 · Cited by 3 · see citing works
“However, in combination with standard rituximab-containing chemotherapy, lenalidomide failed to demonstrate a universal benefit against diffuse large B-cell lymphoma [55, 56].”
BackgroundRoh, J., Yoon, D. H., Lee, Y. K., et al. (2021) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001830 · Cited by 3 · see citing works
Self-citationReproducibility of Gene Expression Signatures in Diffuse Large B-Cell Lymphoma
Plaça, J. R., Diepstra, A., Vries, G. T. L.-D., Mendeville, M., Seitz, A., Lugtenburg, P. J., Zijlstra, J. M., Lam, K. H., Silva, W. A., Ylstra, B., et al. (2022) · Cancers · doi:10.3390/cancers14051346 · Cited by 3 · see citing works
Arthur, S. E., Gao, J., Healy, S., Rushton, C. K., Thomas, N., Hilton, L. K., Dreval, K., Tang, J. S., Alcaide, M., Cojocaru, R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.22.445261 · Cited by 3 · see citing works
Self-citationDiffuse large B-Cell lymphoma: from novel molecular classifications to tailored targeted therapies
Lue, J. K., & Nowakowski, G. S. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.193 · Cited by 2 · see citing works
Self-citationGao, H., Liu, Y., Xu, Y., et al. (2022) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2022.06.003 · Cited by 2 · see citing works
Self-citationMolecular Classification of Diffuse Large B Cell Lymphoma
Whitehair, R. M., Rosti, R. Ö., & Obiorah, I. E. (2023) · Advances in Molecular Pathology · doi:10.1016/j.yamp.2023.06.001 · Cited by 2 · see citing works
Santambrogio, E., Novo, M., Rota‐Scalabrini, D., & Vitolo, U. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1796623 · Cited by 2 · see citing works
Self-citationMolecular Classification of Diffuse Large B-Cell Lymphoma
Baa, A. K., & Rasheed, A. A. (2021) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0041-1735392 · Cited by 1 · see citing works
ASH highlights 2019: “aggressive B-cell lymphoma”
Schmitt, C. A. (2020) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-020-00619-8 · Cited by 1 · see citing works
Popova, V. S. (2021) · Journal of Biomedical and Clinical Research · doi:10.2478/jbcr-2021-0016 · Cited by 1 · see citing works
“…clinical trial is a randomized multicenter study designed to compare the efficacy of the immunomodulator lenalidomide administered at a fixed dose of 15mg from day 1 to day 14, in combination with R-CHOP (R2-CHOP), versus placebo plus R-CHOP in patients with untreated ABC - a subtype of DLBCL [32].”
BackgroundPalmieri, R., Esposito, F., Meconi, F., Rapisarda, V. M., Anemona, L., Paterno, G., Vaccarini, S., Nasso, D., Pupo, L., & Cantonetti, M. (2019) · Case Reports in Hematology · doi:10.1155/2019/2845130
“Volume 2019, Article ID 2845130, 4 pages https://doi.org/10.1155/2019/2845130 nongerminal center diffuse large B-cell non-Hodgkin’s lymphoma (non-GCB DLBCL) was established.”
BackgroundInfluentialAktuelle Standards in der Diagnostik und Therapie aggressiver B-Zell-Lymphome
Friedrichs, B., Schmitz, N., & Lenz, G. (2020) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0949-4745
“[7] Vitolo U, Witzig TE, Gascoyne RD et al.”
BackgroundPatterns of oncogene co-expression at single cell resolution in cancer influence survivalPreprint
Hoppe, M. M., Jaynes, P. W., Shuangyi, F., Peng, Y., Hoang, P. M., Liu, X., Mel, S. D., Poon, L. M., Chan, E. H. L., Lee, J., et al. (2020) · medRxiv · doi:10.1101/2020.10.20.20216101
“However, numerous randomized phase III trials to improve on R-CHOP therapy have been unsuccessful, partly due to the lack of predictive biomarkers to enrich a trial for poor-prognosis cases (3-8).”
BackgroundSelf-citationHentrich, M. (2022) · Deutsche Zeitschrift für Onkologie · doi:10.1055/a-1824-7693
“Untersucht wurden u. a. die Zugabe des Bruton-Ki-nase-Inhibitors Ibrutinib [3], der immunmodulatorischen Substanz Lenalidomid [4] oder des Proteasom-Inhibitors Bortezomib [5], ohne dass sich hierdurch relevante Vorteile ergaben.”
BackgroundFreedman, A. S., & LaCasce, A. S. (2022) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm120.pub2
Ylstra, B., Mendeville, M., Janssen, J., Vries, G. T. L.-D., van Dijk, E., Richter, J., Nijland, M., Roemer, M. G. M., Stathi, P., Hijmering, N. J., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3480882/v1
Li, M., Li, Q., Zhang, Y., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-15477-9
- Authors
- Vitolo, U., Witzig, T. E., Gascoyne, R. D., Scott, D. W., Zhang, Q., Jurczak, W., Özcan, M., Hong, X., Zhu, J., Jin, J., Belada, D., Bergua, J. M., Piazza, F., Mócikova, H., Molinari, A. L., Yoon, D. H., Cavallo, F., Tani, M., Izutsu, K., Kato, K., Czuczman, M., Hersey, S., Kilcoyne, A., Russo, J., Hudak, K., Zhang, J., Chiappella, A., Nowakowski, G. S., & on behalf of the ROBUST study investigators
- Affiliations
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Mayo Clinic (US)
- BC Cancer Agency (CA)
- Harbin Medical University (CN)
- Jagiellonian University (PL)
- Ankara University (TR)
- Fudan University (CN)
- Peking University Cancer Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Charles University (CZ)
- Hospital San Pedro de Alcántara (ES)
- University of Padua (IT)
- Department of Internal Medicine and Haematology Faculty Hospital Kralovske Vinohrady Prague Czech Republic
- Ospedale Infermi di Rimini (IT)
- Asan Medical Center (KR)
- Ospedale "Santa Maria delle Croci" di Ravenna (IT)
- National Cancer Center Hospital (JP)
- Kyushu University (JP)
- Celgene (United States) (US)
- ORCID
- Venue
- Hematological Oncology
- Publisher
- Wiley
- Published
- 2019-06
- Volume
- 37
- Issue
- S2
- Pages
- 36-37
- ISSN
- 0278-0232 (ISSN-L)
- 1099-1069
- OpenAlex
- W2951720456
- Semantic Scholar
- 7e53011e7a595d0a8daf3d2c3c4816e00fb13f0a
- Cited by
- 84
- References
- 0
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 2 · 2022: 7 · 2021: 35 · 2020: 25 · 2019: 12
- FWCI
- 14.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Hematological Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Health Sciences › Medicine › Neurology › CNS Lymphoma Diagnosis and Treatment
- Keywords
- ABC-DLBCL, lenalidomide, R-CHOP, previously untreated lymphoma, progression-free survival, immunomodulators, rituximab, cell of origin, IPI risk stratification, bulky disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
